7 Anhang
7.6 Medianes Patientenüberleben für nicht prognostisch signifikante Faktoren
Tabelle 39: medianes Patientenüberleben in Monaten (mit Confidenzintervall) Faktor Variablen
Alter 40-49 50-59 60-69 >70
Überleben 8,6 (0-22,5) 8,9 (6,9-10,8) 14 (0,7-27,4) 14 (10,3-17,7) Geschlecht Frauen Männer
Überleben 16 (9,5-22,4) 14 (6-21,9)
Schmerz ja nein
Überleben 14 (6,7-21,3) 14,2 (10-18,2)
Ikterus ja nein
Überleben 14,2 (13,9-14,5) 8,1 (3,8-12,5)
Tumorloka-lisation Kopf Körper/Schwanz Überleben 14 (11,3-16,7) 9,9 (0-20,1)
chirurgische
Radikalität R0 R1/2
Überleben 14 (10,2-17,9) 9,9 (4,2-15,6)
Tabelle 40: medianes Patientenüberleben in Monaten (mit Confidenzintervall)
Faktor Variablen
Erweiterung der OP ja nein
Überleben 9,9 (0-20,3) 14 (10,2-17,9)
Tumorgröße T2 T3 T4
Überleben 24,9 (n. b.) 14 (9,7-18,4) 5,713
N-Status N0 N1
Überleben 14,6 (6,3-22,9) 12 (6,8-17,1) beobachtetes
5-Jahres-Überleben (n=2) 0 2
Metastasenstatus M0 M1
Überleben 14 (10,9-17,1) 6,514
Stadium I II III IV
Überleben 24,915 14 (11,1-17,0) 5,716 6,517
Tumorgrading G1 G2 G3
Überleben 17 (7,3-26,8) 14,2 (11,7-16,6) 8,1 (4,2-12)
13 nicht bestimmbar
14 nicht bestimmbar
15 nicht bestimmbar
16 nicht bestimmbar
17 nicht bestimmbar
1. Adam U, Makowiec F, Riediger H, et al.: Risk factors for complications after pancreatic head resection. Am J Surg 2004;187:201-208.
2. Adamek HE, Albert J, Breer H, et al.: Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde
cholangiopancreatography: a prospective controlled study. Lancet 2000;356:190-193.
3. Adler G, Seufferlein T, Bischoff SC, et al.: [S3-Guidelines "Exocrine pancreatic cancer" 2007]. Z Gastroenterol 2007;45:487-523.
4. Alexakis N, Halloran C, Raraty M, et al.: Current standards of surgery for pancreatic cancer. Br J Surg 2004;91:1410-1427.
5. Allendorf JD, Lauerman M, Bill A, et al.: Neoadjuvant Chemotherapy and Radiation for Patients with Locally Unresectable Pancreatic Adenocarcinoma:
Feasibility, Efficacy, and Survival. J Gastrointest Surg 2007.
6. Andren-Sandberg A, Neoptolemos JP: Resection for pancreatic cancer in the new millennium. Pancreatology 2002;2:431-439.
7. Bachellier P, Nakano H, Oussoultzoglou PD, et al.: Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile? Am J Surg 2001;182:120-129.
8. Beger HG, Poch B, Schwarz M, Gansauge F: [Pancreatic cancer. The relative importance of neoadjuvant therapy]. Chirurg 2003;74:202-207.
9. Beger HG, Rau B, Gansauge F, et al.: Treatment of pancreatic cancer: challenge of the facts. World J Surg 2003;27:1075-1084.
10. Beger HG, Treitschke F, Gansauge F, et al.: Tumor of the ampulla of Vater:
experience with local or radical resection in 171 consecutively treated patients.
Arch Surg 1999;134:526-532.
11. Birkmeyer JD, Siewers AE, Finlayson EV, et al.: Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128-1137.
12. Birkmeyer JD, Warshaw AL, Finlayson SR, et al.: Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery 1999;126:178-183.
13. Bramhall SR, Allum WH, Jones AG, et al.: Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 1995;82:111-115.
14. Brennan MF, Kattan MW, Klimstra D, Conlon K: Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg 2004;240:293-298.
15. Breslin TM, Hess KR, Harbison DB, et al.: Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001;8:123-132.
16. Brown HM, Ahrendt SA, Komorowski RA, et al.: Immunohistochemistry and molecular detection of nodal micrometastases in pancreatic cancer. J Surg Res 2001;95:141-146.
17. Buchler MW, Kleeff J, Friess H: Surgical treatment of pancreatic cancer. J Am Coll Surg 2007;205:S81-86.
18. Buck CJ: "Saunders ICD-9-CM: Volumes 1,2&3." W. B. Saunders Company, 2005.
19. Burris HA, 3rd, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
20. Cleary SP, Gryfe R, Guindi M, et al.: Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg
2004;198:722-731.
21. Conlon KC, Klimstra DS, Brennan MF: Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996;223:273-279.
22. Di Giorgio A, Alfieri S, Rotondi F, et al.: Pancreatoduodenectomy for tumors of Vater's ampulla: report on 94 consecutive patients. World J Surg 2005;29:513-518.
23. Everhart J, Wright D: Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. Jama 1995;273:1605-1609.
24. Ferrone CR, Brennan MF, Gonen M, et al.: Pancreatic Adenocarcinoma: The Actual 5-Year Survivors. J Gastrointest Surg 2007.
25. Ferrone CR, Finkelstein DM, Thayer SP, et al.: Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma.
J Clin Oncol 2006;24:2897-2902.
26. Finlayson EV, Goodney PP, Birkmeyer JD: Hospital volume and operative mortality in cancer surgery: a national study. Arch Surg 2003;138:721-725;
discussion 726.
27. Fischer L, Friess H, Z'Graggen K, et al.: [Operative management in the treatment of pancreatic cancer]. Zentralbl Chir 2003;128:390-395.
28. Fischer L, Kleeff J, Friess H, Buchler MW: [Surgical management of pancreatic carcinoma]. Z Gastroenterol 2002;40 Suppl 2:64-67.
29. Fong Y, Gonen M, Rubin D, et al.: Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg 2005;242:540-544; discussion 544-547.
30. Friess H, Kleeff J, Fischer L, et al.: [Surgical standard therapy for cancer of the pancreas]. Chirurg 2003;74:183-190.
31. Gebhardt C, Meyer W, Jurowich C: [Is resection of left-sided ductal pancreatic carcinoma of value?]]. Zentralbl Chir 2000;125:966-969.
32. Gebhardt C, Meyer W, Reichel M, Wunsch PH: Prognostic factors in the operative treatment of ductal pancreatic carcinoma. Langenbecks Arch Surg 2000;385:14-20.
33. Geer RJ, Brennan MF: Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165:68-72; discussion 72-63.
34. Glasbrenner B, Schwarz M, Pauls S, et al.: Prospective comparison of
endoscopic ultrasound and endoscopic retrograde cholangiopancreatography in the preoperative assessment of masses in the pancreatic head. Dig Surg
2000;17:468-474.
35. Gleisner AL, Assumpcao L, Cameron JL, et al.: Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?
Cancer 2007;110:2484-2492.
36. Gordon TA, Bowman HM, Tielsch JM, et al.: Statewide regionalization of pancreaticoduodenectomy and its effect on in-hospital mortality. Ann Surg 1998;228:71-78.
37. Gouma DJ, van Geenen RC, van Gulik TM, et al.: Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg 2000;232:786-795.
38. Gudjonsson B: Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting. J Am Coll Surg
1995;181:483-503.
39. Gudjonsson B: Survival statistics gone awry: pancreatic cancer, a case in point. J Clin Gastroenterol 2002;35:180-184.
40. Han SS, Jang JY, Kim SW, et al.: Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 2006;32:271-275.
41. Hartel M, Niedergethmann M, Farag-Soliman M, et al.: Benefit of venous resection for ductal adenocarcinoma of the pancreatic head. Eur J Surg 2002;168:707-712.
42. Heinemann V, Quietzsch D, Gieseler F, et al.: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-3952.
43. Heinrich S, Schafer M, Bauerfeind P, et al.: [Current diagnosis and treatment of pancreatic cancer]. Schweiz Rundsch Med Prax 2005;94:1243-1254.
44. Henne-Bruns D, Vogel I, Luttges J, et al.: Surgery for ductal adenocarcinoma of the pancreatic head: staging, complications, and survival after regional versus extended lymphadenectomy. World J Surg 2000;24:595-601; discussion 601-592.
45. Herfarth C: [Pancreatic carcinoma--overcome technically but not oncologically].
Chirurg 2003;74:163-164.
46. Holscher AH, Metzger R, Brabender J, et al.: High-volume centers--effect of case load on outcome in cancer surgery. Onkologie 2004;27:412-416.
47. Hopt UT: [Treatment of carcinoma of the pancreatic head]. Zentralbl Chir 2006;131:115-120.
48. Howard JM: Development and progress in resective surgery for pancreatic cancer. World J Surg 1999;23:901-906.
49. Jarufe NP, Coldham C, Mayer AD, et al.: Favourable prognostic factors in a large UK experience of adenocarcinoma of the head of the pancreas and periampullary region. Dig Surg 2004;21:202-209.
50. Kaplan EL MP: Nonparametric-Estimation from Imcomplete Observations.
Journal of the American Statistical Association 1958;53:457-481.
51. Karpoff HM, Klimstra DS, Brennan MF, Conlon KC: Results of total
pancreatectomy for adenocarcinoma of the pancreas. Arch Surg 2001;136:44-47;
discussion 48.
52. Keck T, Makowiec F, Adam U, Hopt UT: [Does hospital volume have influence on the results of pancreatic surgery?]. Zentralbl Chir 2007;132:26-31.
53. Kleeff J, Friess H, Buchler MW: Neoadjuvant therapy for pancreatic cancer. Br J Surg 2007;94:261-262.
54. Kleeff J, Michalski CW, Friess H, Buchler MW: Surgical treatment of pancreatic cancer: the role of adjuvant and multimodal therapies. Eur J Surg Oncol 2007;33:817-823.
55. Klempnauer J, Ridder GJ, Bektas H, Pichlmayr R: [Multivariate analysis of prognostic factors after resection of ductal pancreatic carcinomas]. Langenbecks Arch Chir 1995;380:133-138.
56. Klempnauer J, Ridder GJ, Pichlmayr R: Prognostic factors after resection of ampullary carcinoma: multivariate survival analysis in comparison with ductal cancer of the pancreatic head. Br J Surg 1995;82:1686-1691.
57. Kuhlmann KF, de Castro SM, Wesseling JG, et al.: Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004;40:549-558.
58. Lim JE, Chien MW, Earle CC: Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003;237:74-85.
59. Lowenfels AB, Maisonneuve P: Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 2004;34:238-244.
60. Lowenfels AB, Maisonneuve P, Cavallini G, et al.: Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993;328:1433-1437.
61. Makowiec F, Post S, Saeger HD, et al.: Current practice patterns in pancreatic surgery: results of a multi-institutional analysis of seven large surgical
departments in Germany with 1454 pancreatic head resections, 1999 to 2004 (German Advanced Surgical Treatment study group). J Gastrointest Surg 2005;9:1080-1086; discussion 1086-1087.
62. Manabe T, Ohshio G, Baba N, et al.: Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer 1989;64:1132-1137.
63. Mann O, Strate T, Schneider C, et al.: Surgery for advanced and metastatic pancreatic cancer--current state and perspectives. Anticancer Res 2006;26:681-686.
64. Mao C, Domenico DR, Kim K, et al.: Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies. Arch Surg 1995;130:125-134.
65. Mehta VK, Fisher G, Ford JA, et al.: Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg 2001;5:27-35.
66. Michalski CW, Kleeff J, Jager D, et al.: [Adjuvant treatment of pancreatic cancer]. Dtsch Med Wochenschr 2007;132:803-807.
67. Mukaiya M, Hirata K, Satoh T, et al.: Lack of survival benefit of extended lymph node dissection for ductal adenocarcinoma of the head of the pancreas:
retrospective multi-institutional analysis in Japan. World J Surg 1998;22:248-252; discussion 252-243.
68. Muller MW, Friess H, Kleeff J, et al.: Is there still a role for total pancreatectomy? Ann Surg 2007;246:966-974; discussion 974-965.
69. Nakao A, Harada A, Nonami T, et al.: Clinical significance of carcinoma invasion of the extrapancreatic nerve plexus in pancreatic cancer. Pancreas 1996;12:357-361.
70. Nakao A, Takeda S, Inoue S, et al.: Indications and techniques of extended resection for pancreatic cancer. World J Surg 2006;30:976-982; discussion 983-974.
71. Neoptolemos JP, Raraty MG, Ghaneh P, et al.: [Adjuvant and additive therapy for cancer of the pancreas]. Chirurg 2003;74:191-201.
72. Neoptolemos JP, Russell RC, Bramhall S, Theis B: Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey
of specialist pancreatic units. UK Pancreatic Cancer Group. Br J Surg 1997;84:1370-1376.
73. Neoptolemos JP, Stocken DD, Dunn JA, et al.: Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant
chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234:758-768.
74. Neoptolemos JP, Stocken DD, Friess H, et al.: A randomized trial of
chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-1210.
75. Newman EA, Simeone DM, Mulholland MW: Adjuvant treatment strategies for pancreatic cancer. J Gastrointest Surg 2006;10:916-926.
76. Niedergethmann M, Rexin M, Hildenbrand R, et al.: Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma. Am J Surg Pathol 2002;26:1578-1587.
77. Oettle H, Post S, Neuhaus P, et al.: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer:
a randomized controlled trial. Jama 2007;297:267-277.
78. Okusaka T, Yamada T, Maekawa M: Serum tumor markers for pancreatic cancer: the dawn of new era? Jop 2006;7:332-336.
79. Pedrazzoli S, Beger HG, Obertop H, et al.: A surgical and pathological based classification of resective treatment of pancreatic cancer. Summary of an international workshop on surgical procedures in pancreatic cancer. Dig Surg 1999;16:337-345.
80. Pedrazzoli S, DiCarlo V, Dionigi R, et al.: Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998;228:508-517.
81. Picozzi VJ, Kozarek RA, Traverso LW: Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003;185:476-480.
82. Povoski SP, Karpeh MS, Jr., Conlon KC, et al.: Association of preoperative biliary drainage with postoperative outcome following
pancreaticoduodenectomy. Ann Surg 1999;230:131-142.
83. Reissfelder C, Koch M, Buchler MW, Weitz J: [Pancreatic carcinoma.]. Chirurg 2007;78:1059-1072.
84. Riall TS, Cameron JL, Lillemoe KD, et al.: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma--part 3: update on 5-year survival. J Gastrointest Surg 2005;9:1191-1204; discussion 1204-1196.
85. Richter A, Niedergethmann M, Sturm JW, et al.: Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003;27:324-329.
86. Ridwelski K, Meyer F, Schmidt U, Lippert H: [Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection]. Zentralbl Chir 2005;130:353-361.
87. Roder JD, Thorban S, Pantel K, Siewert JR: Micrometastases in bone marrow:
prognostic indicators for pancreatic cancer. World J Surg 1999;23:888-891.
88. Roeder N, Wenke A, Heumann M, Franz D: [Volume outcome relationship : Consequences of reallocation of minimum volume based on current German surgical regulations.]. Chirurg 2007;78:1018-1027.
89. Sasson AR, Hoffman JP, Ross EA, et al.: En bloc resection for locally advanced cancer of the pancreas: is it worthwhile? J Gastrointest Surg 2002;6:147-157;
discussion 157-148.
90. Scheunemann P, Stoecklein NH, Rehders A, et al.: Occult tumor cells in lymph nodes as a predictor for tumor relapse in pancreatic adenocarcinoma.
Langenbecks Arch Surg 2007.
91. Schnelldorfer T, Adams DB, Warshaw AL, et al.: Forgotten pioneers of pancreatic surgery: beyond the favorite few. Ann Surg 2008;247:191-202.
92. Seiler CA, Wagner M, Bachmann T, et al.: Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results. Br J Surg 2005;92:547-556.
93. Sewnath ME, Birjmohun RS, Rauws EA, et al.: The effect of preoperative biliary drainage on postoperative complications after pancreaticoduodenectomy.
J Am Coll Surg 2001;192:726-734.
94. Shen M, Boffetta P, Olsen JH, et al.: A pooled analysis of second primary pancreatic cancer. Am J Epidemiol 2006;163:502-511.
95. Shimizu Y, Yasui K, Matsueda K, et al.: Small carcinoma of the pancreas is curable: new computed tomography finding, pathological study and
postoperative results from a single institute. J Gastroenterol Hepatol 2005;20:1591-1594.
96. Shoup M, Conlon KC, Klimstra D, Brennan MF: Is extended resection for adenocarcinoma of the body or tail of the pancreas justified? J Gastrointest Surg 2003;7:946-952; discussion 952.
97. Siess M, Siewert JR: [Patient safety in view of specialization, minimum quantity and regionalization]. Dtsch Med Wochenschr 2005;130:503-507.
98. Silverman DT, Dunn JA, Hoover RN, et al.: Cigarette smoking and pancreas cancer: a case-control study based on direct interviews. J Natl Cancer Inst 1994;86:1510-1516.
99. Silverman DT, Schiffman M, Everhart J, et al.: Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999;80:1830-1837.
100. Snady H, Bruckner H, Cooperman A, et al.: Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000;89:314-327.
101. Sohn TA, Yeo CJ, Cameron JL, et al.: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-579.
102. Sohn TA, Yeo CJ, Cameron JL, et al.: Should pancreaticoduodenectomy be performed in octogenarians? J Gastrointest Surg 1998;2:207-216.
103. Sohn TA, Yeo CJ, Cameron JL, et al.: Do preoperative biliary stents increase postpancreaticoduodenectomy complications? J Gastrointest Surg 2000;4:258-267; discussion 267-258.
104. Sperti C, Pasquali C, Pedrazzoli S: Ductal adenocarcinoma of the body and tail of the pancreas. J Am Coll Surg 1997;185:255-259.
105. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S: Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997;21:195-200.
106. Stewart CJ, Mills PR, Carter R, et al.: Brush cytology in the assessment of pancreatico-biliary strictures: a review of 406 cases. J Clin Pathol 2001;54:449-455.
107. Stocken DD, Buchler MW, Dervenis C, et al.: Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005;92:1372-1381.
108. Takai S, Satoi S, Toyokawa H, et al.: Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience. Pancreas 2003;26:243-249.
109. Tran KT, Smeenk HG, van Eijck CH, et al.: Pylorus preserving
pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and
periampullary tumors. Ann Surg 2004;240:738-745.
110. Traverso LW: Pancreatic cancer: surgery alone is not sufficient. Surg Endosc 2006;20 Suppl 2:S446-449.
111. Trede M, Saeger HD, Schwall G, Rumstadt B: Resection of pancreatic cancer--surgical achievements. Langenbecks Arch Surg 1998;383:121-128.
112. Tsuchiya R, Noda T, Harada N, et al.: Collective review of small carcinomas of the pancreas. Ann Surg 1986;203:77-81.
113. Wagner M, Redaelli C, Lietz M, et al.: Curative resection is the single most important factor determining outcome in patients with pancreatic
adenocarcinoma. Br J Surg 2004;91:586-594.
114. Welzel TM, Vick C, Reiser M, Goke B: [Diagnostic evaluation of pancreatic carcinoma prompting treatment decisions]. Chirurg 2003;74:171-182.
115. Wenger FA, Peter F, Zieren J, et al.: Prognosis factors in carcinoma of the head of the pancreas. Dig Surg 2000;17:29-35.
116. WHO: "Icd-10: International Statistical Classification of Diseases and Related Health Problems: Alphabetical Index: 3." World Health Organization, 2005.
117. Wilkowski R, Thoma M, Schauer R, et al.: Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg 2004;28:1011-1018.
118. Wittekind Ch MH-J, Bootz F: "TNM. Klassifikation maligner Tumoren, 6.
Auflage." Springer, 2002.
119. Wittekind Ch WG: "TNM-Klassifikation maligner Tumoren, 5. Auflage."
Springer, 1997.
120. Wolff H: [Evolution of the treatment of pancreatic cancer]. Zentralbl Chir 2003;128:443-447.
121. Yeo CJ, Abrams RA, Grochow LB, et al.: Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225:621-633; discussion 633-626.
122. Yeo CJ, Cameron JL, Sohn TA, et al.: Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg 1999;229:613-622; discussion 622-614.
123. Yeo CJ, Sohn TA, Cameron JL, et al.: Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 1998;227:821-831.
!"?#"!@""!$8F
+''8F+''0!?!!$$@
&'
G$""!$D"$"$$!/=!$$!/>$$!
''8+''0!?!!$$@
(#!$)
-#D "$>H!
<G;
!"'1'F1''0!?!!$$@
"#!$%# !
.!"??"
2GI
%"")D1'1
%"$"D=$%?
;)!!"D!
""J!:!"D"
Mein besonderer Dank gilt:
Herrn Prof. J. Jähne, meinem Doktorvater, für die Überlassung des Themas, die hervorragende Betreuung und die konstruktive Kritik.
Genauso seiner Sekretärin, Frau Dagmar Nentwich, die für mich immer ansprechbar war und mir bei jeder Frage hilfreich zur Seite stand.
Frau Dr. med. Dankoweit-Timpe für ihre freundliche Unterstützung bei pathologischen Fragestellungen und für die Fotografien der Resektate.
Herrn Dr. rer. nat. habil. Ludwig Hoy vom Institut für Biometrie der MHH für die statistische Betreuung der Arbeit.
Dr. med. Karsten Wegner, meinem Onkel, für die Hilfestellung beim Einarbeiten in die Statistik.
Meinen Eltern, besonders meinem Vater, für die Unterstützung während der Doktorarbeit.
Ich erkläre, daß ich die der Medizinischen Hochschule Hannover zur Promotion eingereichte Dissertation mit dem Titel
Die chirurgische Therapie des Pankreaskarzinoms – Eine retrospektive Analyse unter besonderer Berücksichtigung
prognostischer Parameter
in der Klinik für Allgemein- und Viszeralchirurgie, Zentrum Chirurgie, des Diakoniekrankenhauses Henriettenstiftung in Hannover (Leiter: Prof. Dr. med. J. Jähne) unter der Betreuung von Prof. Dr. med. J. Jähne ohne sonstige Hilfe durchgeführt und bei der Abfassung der Dissertation keine anderen als die dort aufgeführten Hilfsmittel benutzt habe. Ich habe bisher an keiner in- oder ausländischen Medizinischen Fakultät ein Gesuch um Zulassung zur Promotion eingereicht, noch diese oder eine andere Arbeit als Dissertation vorgelegt. Teile der Dissertation sollen in folgendem Publikationsorgan veröffentlicht werden:
Der Chirurg
Die Dissertation wurde in Auszügen bei folgenden Veranstaltungen vorgestellt:
Vortrag:
1) J. Jähne, M. Bröse: Chirurgische Therapie der Pankreasneoplasie 2. Viszeralmedizinisches Seminar, 19.01.08, Hannover
2) J. Jähne, M. Bröse: Leitlinien-orientierte chirurgische Therapie des Pankreaskarzinoms
Fortbildungsveranstaltung des Gastro-Clubs Hamburg, 27.02.08, Hamburg
Hannover, den 25.4.2008